Nasdaq · CIK 0002010788
EXOZ EXOZYMES INC.
Insider trading from SEC Form 4. Last filing 26 d ago. Close $5.25 on Oct 9, 2026, +19% from the 52-week low and -68% from the high.
EXOZYMES INC. (EXOZ) has 17 SEC Form 4 filings on file from 6 insiders, the latest filed on Sep 17, 2026. In the last 90 days insiders made 1 open-market buy worth $6,405 and 0 open-market sells worth $0, net +$6,405.
5 open-market trades have been scored at EXOZ. The newest: Michael Heltzen (Chief Executive Officer) bought $6,405 of stock on Aug 25, 2026, filed Sep 2, 2026, scored 28 (weak). The largest of the 5 shown: Michael Heltzen (Chief Executive Officer) bought $22k on Nov 15, 2024, scored 33 (weak).
EXOZ closed at $5.25 on Oct 9, 2026, 19% above its 52-week low and 68% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at EXOZYMES INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | Michael Heltzen Chief Executive Officer buy | $6,405 855 shares | +6% | - | |
| 15Weak | Tyler Paz Korman Chief Scientific Officer sell | $15k 1,500 shares | -0% | +47% from low-37% from high | |
| 36Weak | Michael Heltzen Chief Executive Officer buy | $11k 1,040 shares | +11% | +18% from low-50% from high | |
| 40Moderate | Michael Heltzen Chief Executive Officer buy | $20k 1,888 shares | +95% | - | |
| 33Weak | Michael Heltzen Chief Executive Officer buy | $22k 1,984 shares | - | - |
Transactions
Every row filed, 25 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Fouad Nawaz Vice President- Finance | AGrant or award Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | 26 d ago |
| Aug 26, 2026 | Michael Heltzen Chief Executive Officer | POpen-market purchase Common Stock | +4 | $7.58 | $30 | 14,708 | 41 d ago |
| Aug 26, 2026 | Michael Heltzen Chief Executive Officer | POpen-market purchase Common Stock | +251 | $7.35 | $1,845 | 14,704 | 41 d ago |
| Aug 26, 2026 | Michael Heltzen Chief Executive Officer | POpen-market purchase Common Stock | +250 | $7.60 | $1,900 | 14,453 | 41 d ago |
| Aug 25, 2026 | Michael Heltzen Chief Executive Officer | POpen-market purchase Common Stock | +250 | $7.52 | $1,880 | 14,203 | 41 d ago |
| Aug 25, 2026 | Michael Heltzen Chief Executive Officer | POpen-market purchase Common Stock | +100 | $7.50 | $750 | 13,953 | 41 d ago |
| Aug 19, 2026 | Michael Heltzen Chief Executive Officer | AGrant or award Common Stock | +8,841 | $6.40 | $57k | 13,853 | 41 d ago |
| Apr 8, 2026 | Tyler Paz Korman Chief Scientific Officer | SOpen-market sale COMMON STOCK | -750 | $10.04 | $7,530 | 729,873 | Apr 10, 2026 |
| Apr 9, 2026 | Tyler Paz Korman Chief Scientific Officer | SOpen-market sale COMMON STOCK | -750 | $10.53 | $7,894 | 729,123 | Apr 10, 2026 |
| Apr 1, 2026 | Damien Alan Perriman Chief Commercial Officer | AGrant or award COMMON STOCK | +8,887 | $8.44 | $75k | 0 | Apr 8, 2026 |
| Apr 1, 2026 | Damien Alan Perriman Chief Commercial Officer | AGrant or award Restricted Stock Grant for Common Stock | +62,759 | $0.00 | $0 | 62,759 | Apr 8, 2026 |
| Apr 1, 2026 | Paul Hideo Opgenorth Vice President, Development | AGrant or award COMMON STOCK | +3,999 | $8.44 | $34k | 645,149 | Apr 8, 2026 |
| Apr 1, 2026 | Fouad Nawaz Vice President- Finance | AGrant or award COMMON STOCK | +5,999 | $8.44 | $51k | 9,488 | Apr 8, 2026 |
| Apr 1, 2026 | Tyler Paz Korman Chief Scientific Officer | AGrant or award COMMON STOCK | +5,332 | $8.44 | $45k | 730,623 | Apr 8, 2026 |
| Apr 1, 2026 | Damien Alan Perriman Chief Commercial Officer | AGrant or award Stock Option for Common Stockderivative | +146,437 | $0.00 | $0 | 146,437 | Apr 8, 2026 |
| Jul 2, 2025 | Michael Heltzen Chief Executive Officer | POpen-market purchase Common Stock | +1,040 | $10.22 | $11k | 10,629 | Jul 2, 2025 |
| Jun 17, 2025 | Michael Heltzen Chief Executive Officer | AGrant or award Stock Options for Common Stockderivative | +235,817 | $0.00 | $0 | 235,817 | Jun 20, 2025 |
| Jun 16, 2025 | Tyler Paz Korman Vice President, Research | AGrant or award Common Stock | +2,990 | $12.54 | $37k | 725,291 | Jun 17, 2025 |
| Jun 13, 2025 | Fouad Nawaz Vice President, Finance | AGrant or award Common Stock | +3,489 | $12.54 | $44k | 3,489 | Jun 17, 2025 |
| Jun 13, 2025 | Paul Hideo Opgenorth Vice President, Development | AGrant or award Common Stock | +2,990 | $12.54 | $37k | 641,150 | Jun 17, 2025 |
| Jan 16, 2025 | Michael Heltzen Chief Executive Officer | POpen-market purchase Common Stock | +121 | $10.72 | $1,297 | 2,105 | Jan 21, 2025 |
| Jan 17, 2025 | Michael Heltzen Chief Executive Officer | POpen-market purchase Common Stock | +1,767 | $10.78 | $19k | 3,872 | Jan 21, 2025 |
| Nov 15, 2024 | Michael Heltzen Chief Executive Officer | POpen-market purchase Common Stock | +1,984 | $11.10 | $22k | 1,984 | Nov 19, 2024 |
| Nov 8, 2024 | MDB Capital Holdings, LLC owner | CConversion Common Stock | +122,657 | $6.40 | $785k | 3,931,133 | Nov 18, 2024 |
| Nov 8, 2024 | Paul Hideo Opgenorth Vice President, Development | CConversion Common Stock | +2,344 | $6.40 | $15k | 640,504 | Nov 18, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Michael HeltzenChief Executive Officer
- Tyler Paz KormanChief Scientific Officer
- MDB Capital Holdings, LLCowner
- Fouad NawazVice President- Finance
- Paul Hideo OpgenorthVice President, Development
- Damien Alan PerrimanChief Commercial Officer
Questions about EXOZ
Answered from the filings on this page, as of the latest one.
Are insiders buying EXOZ?
As of Sep 17, 2026, SEC Form 4 filings show 1 open-market buy worth $6,405 by 1 insider and 0 open-market sells worth $0 by 0 insiders at EXOZYMES INC. in the last 90 days, net +$6,405. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade EXOZ on the open market?
Michael Heltzen (Chief Executive Officer) bought $6,405 of EXOZ on Aug 25, 2026 and filed the Form 4 on Sep 2, 2026. InsiderTell scored 28 (weak).
How many insiders file Form 4 at EXOZYMES INC.?
6 people have filed a Form 4 at EXOZYMES INC., among them Michael Heltzen (Chief Executive Officer), Tyler Paz Korman (Chief Scientific Officer), MDB Capital Holdings, LLC (10% owner). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.